The review concluded that incidence of peripheral oedema and patient withdrawal increased with duration of calcium channel blocker therapy up to six months. Rates were lower with both non-dihydropyridines and lipophilic dihydropyridines. Given lack of clarity on quality and potential for bias in the review process, the authors' conclusions should be considered tentative.
Study selection
Randomised controlled trials (RCTs) of hypertensive participants that compared CCBs with other agents (including placebo) were eligible for inclusion. Trials were required to have a sample size of at least 100 participants who took CCBs. Trial duration needed to be at least four weeks. Trials had to report data on peripheral oedema. Abstracts, studies of patients with coronary heart disease or heart failure and studies of mibefradil were excluded. Participants in the included studies had a mean age of 56 years and 56% were male. CCBs included amlodipine, nifedipine, diltiazem, felodipine, isradipine, lacidipine, lercanidipine, verapamil, nitrendipine, nisoldipine, barnidipine, manidipine, nicardipine and pranidipine. CCBs were compared with control groups that included placebo and active antihypertensive therapies such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, other CCBs, direct renin inhibitors and thiazides. A broad definition of oedema was used and was mostly assessed by self report; a few trials supplementing self report with a symptom questionnaire and/or measurement by the examiner.
The authors did not state how many reviewers selected studies for the review.
Assessment of study quality
Studies were assessed for quality using the Cochrane Collaboration risk of bias tool; seven criteria were used but the details of these criteria were not reported. For each criterion, studies were described as being at low, unclear or high risk of bias. Composite scores for each study were also defined as low risk (seven of seven criteria at low risk of bias), intermediate risk (six of seven criteria at low risk of bias) and high risk (five or fewer criteria at low risk of bias).
The authors did not state how many reviewers assessed the included studies for quality.
Data extraction
Incidence of peripheral oedema, proportion of withdrawals from treatment, relative risks (RRs) of peripheral oedema and withdrawal due to oedema by different types of CCB and 95% confidence intervals (CIs) were calculated using the intention-to-treat principle.
Two reviewers independently extracted data in duplicate. Disagreements were resolved by consensus.
Methods of synthesis
Studies were combined and the results reported in narrative synthesis for weighted incidence of oedema and withdrawal 
Results of the review
One hundred and six studies with 125 comparison arms (99,469 participants) were included in the review. Sixteen trials were at high risk of bias; the others were either low or intermediate risk of bias. Follow-up ranged from one to 66 months; for most trials follow-up was six months or less.
Incidence of peripheral oedema: At mean follow-up of 27 weeks and compared to control with a peripheral oedema rate of 3.2% (95% CI 3.1 to 3.3), CCBs were associated with a significantly higher peripheral oedema rate (10.7%, 95% CI 10.6 to 10.9; number of studies not reported). Incidence of peripheral oedema increased with duration of CCB therapy from 2.3% at four weeks to 23.8% at 26 weeks or greater (number of studies not reported).
Dosage of CCB significantly influenced peripheral oedema rates: incidence of oedema was 5.7% (95% CI 5.5 to 5.9) with low-dose CCBs and 16.1% (95% CI 15.9 to 16.3) with high-dose CCBs (number of studies not reported).
Compared to non-DHPs with a oedema rate of 3.1% (95% CI 2.8 to 3.4), DHPs were associated with a significantly higher incidence of peripheral oedema (12.3%, 95% CI 12.2 to 12.5; number of studies not reported). Compared to traditional DHPs, the risk of peripheral oedema with lipophilic DHPs was significantly lower (RR 0.43, 95% CI 0.34 to 0.53; six trials, no heterogeneity).
Patient withdrawal due to peripheral oedema: Compared to control with a patient withdrawal rate of 0.5% (95% CI 0.36 to 0.58), CCBs were associated with a significantly higher patient withdrawal rate (2.1%, 95% CI 1.9 to 2.2; 39 trials). Incidence of patient withdrawal increased with duration of CCB therapy from 1% at four weeks to 5.5% with long-term use (number of studies not reported).
Compared to non-DHPs with a withdrawal rate of 0.6% (95% CI 0.35 to 0.85), DHPs were associated with significantly higher withdrawal rates (2.4%, 95% CI 2.2 to 2.5; number of studies not reported). Compared to traditional DHPs, the risk of withdrawal with lipophilic DHPs was significantly lower (RR 0.22, 95% CI 0.12 to 0.40; six trials).
There was no evidence of publication bias.
